![Daniel Bolanowski](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Daniel Bolanowski
Analyst-Equity chez
Arctic Asset Management AS (Sweden)
Profil
Mr. Daniel Bolanowski is a Portfolio Manager at Arctic Asset Management AS.
He fills the role as an Analyst and has the responsibility of reaserch, value tracking.
valuation, opportunity sourcing.
He has more than 5 years of experience as business analyst and has had several engagements for small biotech/medtech companies.
Mr. Bolanowski worked as a Business Analyst at Karolinska Development AB, a Head-Business Development at Akinion Pharmaceuticals AB and Axelar AB.
He has a MSc in Biotechnology and a MSc in Business & Economics from the University of Uppsala.
Postes actifs de Daniel Bolanowski
| Sociétés | Poste | Début |
|---|---|---|
Arctic Asset Management AS (Sweden)
 Arctic Asset Management AS (Sweden) Investment ManagersFinance AAM-Sweden employs an active approach that focuses on bringing long-term value creation to their clients. The firm’s Arctic Aurora LifeScience is a specialized global healthcare equity UCITS fund that invests primarily in European and US public life science companies. The investment strategy focuses on achieving excess return from investments in the biotechnology and pharmaceutical sector by investing in the most innovative companies developing new treatments that significantly change the life of patients to the benefit of society. | Analyst-Equity | 01/01/2016 |
Anciens postes connus de Daniel Bolanowski
| Sociétés | Poste | Fin |
|---|---|---|
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development seeks investment in companies located in the Nordic region, primarily in Swedish. The firm targets companies operating in the fields of health technology, health services, medical devices, technology services, life science. It provides financing for early stage capital requirements. It takes a seat on the board of directors. | Analyste en capital-investissement | 31/12/2015 |
| KDVENTURES AB | Corporate Officer/Principal | 01/12/2015 |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical for the treatment of acute myeloid leukemia | Corporate Officer/Principal | - |
Axelar AB
 Axelar AB BiotechnologyHealth Technology Provides oral anti-cancer therapies | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
35
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development seeks investment in companies located in the Nordic region, primarily in Swedish. The firm targets companies operating in the fields of health technology, health services, medical devices, technology services, life science. It provides financing for early stage capital requirements. It takes a seat on the board of directors. | Finance |
Axelar AB
Axelar AB BiotechnologyHealth Technology Provides oral anti-cancer therapies | Health Technology |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical for the treatment of acute myeloid leukemia | Health Technology |
Karolinska Development AB
 Karolinska Development AB Financial ConglomeratesFinance Operates as a life sciences investment company | Finance |
Arctic Asset Management AS (Sweden)
Arctic Asset Management AS (Sweden) Investment ManagersFinance AAM-Sweden employs an active approach that focuses on bringing long-term value creation to their clients. The firm’s Arctic Aurora LifeScience is a specialized global healthcare equity UCITS fund that invests primarily in European and US public life science companies. The investment strategy focuses on achieving excess return from investments in the biotechnology and pharmaceutical sector by investing in the most innovative companies developing new treatments that significantly change the life of patients to the benefit of society. | Finance |
